drugset / Trial / NCT02481947

A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults

NCT02481947

Phase 3 Completed 459 enrolled Braintree Laboratories
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate a daily dose of BLI400 Laxative for safety and efficacy versus lubiprostone in constipated adults.

Timeline

Start
2015-05
Primary completion
2015-11
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject BLI400 Laxative Unknown 21 g
Comparator Lubiprostone Small molecule 24 ug

Indications